

# Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

M. A. Bendary<sup>1</sup>

<sup>1</sup> King Abdul Aziz University

**Potential competing interests:** No potential competing interests to declare.

Dear Editor-in-Chief,

Thank you for giving me the opportunity to evaluate this review titled "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol".

In a Snapshot of this article, the is original and interesting.

In the abstract, the focus and relevance of the manuscript are clearly described.

In the introduction: The context, relevance, and need for the research have been correctly framed and supported with relevant published studies. Also, the current state of knowledge about the field is accurately represented. Along with a clear research question

In the method: the study design is clear, and it is described in sufficient detail so that the work can be replicated.

**However**, I have little comment on the number of animals per group; I think 4 animals per group are not satisfactory for performing statistical analysis, and using ketamine in anesthesia is not preferable.

In the results, all study questions have been addressed and are presented clearly, supported by statistical analysis methods. Well-designed tables, figures, and graphs.

In the discussion, the authors found the right balance between presenting results so that the broader context is discussed rather than a rephrasing of the key results.

References are

**I recommend this manuscript to be published in the Qeios journal**

Yours,

Prof. MA. Bendary

Professor of Clinical Physiology, King Abdul Aziz Medical College, Saudi Arabia

